FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313644816> ?p ?o ?g. }

• W4313644816 endingPage "227" @default.
• W4313644816 startingPage "219" @default.
• W4313644816 abstract "Abstract Patients with human papillomavirus type 16 (HPV16) infection and low-grade cervical dysplasia [low-grade squamous intraepithelial lesion (LSIL)/CIN1] or atypical squamous cells [atypical squamous cells of undetermined significance (ASC-US)/atypical squamous cells- cannot exclude high-grade squamous intraepithelial lesion (ASC-H)] require active surveillance for disease progression. A safe and effective immunotherapy to clear HPV16 is an unmet medical need. The safety run-in cohort of a randomized double-blind, placebo-controlled phase II trial of PVX2 [vaccination twice with HPV16-targeting pNGVL4a-Sig/E7(detox)/HSP70 plasmid and once with the HPV16 L2E7E6 fusion protein “TA-CIN”] as immunotherapy for patients with HPV16+ ASC-US, ASC-H, or LSIL/CIN1 (NCT03911076) was recently completed. The primary objective of this cohort was to determine the safety and tolerability of PVX2 vaccination. Subjects were confirmed to have HPV16 infection and LSIL/CIN1, ASC-US, or ASC-H. Adverse events were evaluated using Common Terminology Criteria for Adverse Events v5.0. HPV typing by HPV16 18/45 Aptima Assay was done at baseline, month 6, and month 12, with simultaneous cytology analysis. Cervical biopsies and endocervical curettage were performed at baseline and month 6. In the safety run-in cohort 12 eligible patients were enrolled. Each received three monthly immunizations. One was lost to follow-up after week 12. There were no serious adverse events. A total of five adverse events were noted by 4 patients; 4 were considered not vaccine-related, and one ‘unlikely related’ by the investigator. At month 6, 45% (5/11) of participants converted to HPV16-negative and 2 others developed CIN2+ and received a loop electrosurgical excision procedure. At month 12, 64% (7/11) were HPV16-negative, including those HPV16-negative at month 6. In conclusion, PVX2 immunotherapy was well tolerated and associated with viral regression, supporting further testing. Prevention Relevance: This safety run-in study cohort suggests that PVX2 immunotherapy is well tolerated in the target population and is sufficiently safe to warrant further clinical testing in a randomized study. The combined vaccines may facilitate higher-than-expected rate of human papillomavirus type 16 viral clearance 6 and 12 months after treatment, although this requires validation." @default.
• W4313644816 created "2023-01-07" @default.
• W4313644816 creator A5006924305 @default.
• W4313644816 creator A5024186639 @default.
• W4313644816 creator A5025728397 @default.
• W4313644816 creator A5031318982 @default.
• W4313644816 creator A5052752732 @default.
• W4313644816 creator A5084051601 @default.
• W4313644816 creator A5089035026 @default.
• W4313644816 date "2023-01-05" @default.
• W4313644816 modified "2023-10-18" @default.
• W4313644816 title "Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1" @default.
• W4313644816 cites W1529655352 @default.
• W4313644816 cites W154951103 @default.
• W4313644816 cites W1976393621 @default.
• W4313644816 cites W2004405589 @default.
• W4313644816 cites W2012813126 @default.
• W4313644816 cites W2020573981 @default.
• W4313644816 cites W2023391039 @default.
• W4313644816 cites W2042308547 @default.
• W4313644816 cites W2060353879 @default.
• W4313644816 cites W2060786724 @default.
• W4313644816 cites W2065695118 @default.
• W4313644816 cites W2075059757 @default.
• W4313644816 cites W2113960129 @default.
• W4313644816 cites W2115104124 @default.
• W4313644816 cites W2129698576 @default.
• W4313644816 cites W2136111158 @default.
• W4313644816 cites W2159416556 @default.
• W4313644816 cites W2160435269 @default.
• W4313644816 cites W2179671231 @default.
• W4313644816 cites W2276203028 @default.
• W4313644816 cites W3015112546 @default.
• W4313644816 cites W3048372648 @default.
• W4313644816 cites W3116862386 @default.
• W4313644816 cites W3122088738 @default.
• W4313644816 cites W3137085874 @default.
• W4313644816 cites W3203488151 @default.
• W4313644816 doi "https://doi.org/10.1158/1940-6207.capr-22-0413" @default.
• W4313644816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36607735" @default.
• W4313644816 hasPublicationYear "2023" @default.
• W4313644816 type Work @default.
• W4313644816 citedByCount "1" @default.
• W4313644816 countsByYear W43136448162023 @default.
• W4313644816 crossrefType "journal-article" @default.
• W4313644816 hasAuthorship W4313644816A5006924305 @default.
• W4313644816 hasAuthorship W4313644816A5024186639 @default.
• W4313644816 hasAuthorship W4313644816A5025728397 @default.
• W4313644816 hasAuthorship W4313644816A5031318982 @default.
• W4313644816 hasAuthorship W4313644816A5052752732 @default.
• W4313644816 hasAuthorship W4313644816A5084051601 @default.
• W4313644816 hasAuthorship W4313644816A5089035026 @default.
• W4313644816 hasBestOaLocation W43136448161 @default.
• W4313644816 hasConcept C121608353 @default.
• W4313644816 hasConcept C126322002 @default.
• W4313644816 hasConcept C197934379 @default.
• W4313644816 hasConcept C2775924586 @default.
• W4313644816 hasConcept C2777343196 @default.
• W4313644816 hasConcept C2778220009 @default.
• W4313644816 hasConcept C2778375690 @default.
• W4313644816 hasConcept C71924100 @default.
• W4313644816 hasConcept C72563966 @default.
• W4313644816 hasConceptScore W4313644816C121608353 @default.
• W4313644816 hasConceptScore W4313644816C126322002 @default.
• W4313644816 hasConceptScore W4313644816C197934379 @default.
• W4313644816 hasConceptScore W4313644816C2775924586 @default.
• W4313644816 hasConceptScore W4313644816C2777343196 @default.
• W4313644816 hasConceptScore W4313644816C2778220009 @default.
• W4313644816 hasConceptScore W4313644816C2778375690 @default.
• W4313644816 hasConceptScore W4313644816C71924100 @default.
• W4313644816 hasConceptScore W4313644816C72563966 @default.
• W4313644816 hasFunder F4320309684 @default.
• W4313644816 hasIssue "4" @default.
• W4313644816 hasLocation W43136448161 @default.
• W4313644816 hasLocation W43136448162 @default.
• W4313644816 hasLocation W43136448163 @default.
• W4313644816 hasOpenAccess W4313644816 @default.
• W4313644816 hasPrimaryLocation W43136448161 @default.
• W4313644816 hasRelatedWork W1556562895 @default.
• W4313644816 hasRelatedWork W2087016115 @default.
• W4313644816 hasRelatedWork W2160729253 @default.
• W4313644816 hasRelatedWork W2349164817 @default.
• W4313644816 hasRelatedWork W2363981502 @default.
• W4313644816 hasRelatedWork W2504763072 @default.
• W4313644816 hasRelatedWork W2603773853 @default.
• W4313644816 hasRelatedWork W3128855896 @default.
• W4313644816 hasRelatedWork W3189762672 @default.
• W4313644816 hasRelatedWork W4251165208 @default.
• W4313644816 hasVolume "16" @default.
• W4313644816 isParatext "false" @default.
• W4313644816 isRetracted "false" @default.
• W4313644816 workType "article" @default.